Connect with us

Psilocybin

News You Might Have Missed: April 11th, 2022

The article News You Might Have Missed: April 11th, 2022 was originally published on Microdose.

  Welcome to the News You Might Have Missed, a weekly…

Published

on

The article News You Might Have Missed: April 11th, 2022 was originally published on Microdose.

 

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed. 

It was a busy week with lots of news, have a look and see you next week for another update.

 

Field Trip Granted Patent for Lead Compound FT-104

Field Trip has continued to deliver on their projected milestones with the announcement that the patent has been formally granted and gives exclusive rights to Field Trip for the composition of matter, use, and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including FT-104. The patent will provide protection until 2040.

 

Awakn Successfully Completes Phase One of Its Drug Discovery Program

Professor David Nutt, Awakn’s Chief Research Officer: “I am so pleased that this unique and innovative program has progressed so quickly. We have patented two novel molecular series that so far replicate the in-vitro effects of MDMA and which are now ready to be optimised for the next step of in-vivo studies, which are needed before proceeding into humans”.

 

Universal Ibogaine Lists on the Frankfurt Stock Exchange

The company’s common shares have been approved for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt (the “FSE”) under the ticker symbol “JC4”.  UI will continue to trade in Canada on the TSX Venture Exchange under its current ticker symbol IBO and on the OTCQB under the ticker symbol IBOGF. 

 

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

“We’d like to congratulate Nick and his team for the ground-breaking work that they have done in developing GMP, medical grade MDMA for use in clinical trials and regulatory approved expanded access schemes,” said Peter Hunt, Board Chair of Mind Medicine Australia. “There is a desperate need for innovation in the mental health sector for hard-to-treat illnesses such as post-traumatic stress disorder which cause enormous suffering.  Clinical trials have shown that MDMA assisted therapy is safe to use in clinically controlled environments and can achieve high remission rates for people suffering from post-traumatic stress disorder”.

 

PharmaDrug Advances DMT-Analogue Program for Glaucoma with Production of Medical Device

  • Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues
  • In vitro, time dependent drug elution profile evaluated for three candidate molecules
  • Biocompatibility of drug-loaded medical device demonstrates cell-based safety at doses anticipated to be within therapeutic range
  • Current results provide Company with refined focus for two candidate molecules

 

Novamind Opens 8th Integrative Psychiatry Clinic

The Phoenix Clinic—Novamind’s second clinic in Arizona—is staffed with a multidisciplinary team of prescribing providers and therapists and offers a range of mental health services including treatment programs for ADHD, depression, OCD, autism, eating disorders, anxiety, sexual and physical trauma, and PTSD. The team has advanced training in child and adolescent psychiatry and is also specialized in care for military and first responders.

 

Nova Mentis to Produce Psilocybin Capsules for Phase 2A Clinical Study

NOVA is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of FXS. Furthermore, NOVA has manufactured a large supply of >98% pure psilocybin for clinical studies and commercialization following drug approval.

 

Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed

 

Read More

Trending